{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.0","upperLimit":"36.8","value":"15.1"},{"groupId":"OG001","lowerLimit":"68.5","upperLimit":"391.7","value":"178.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Concentration of lenalidomide obtained from any day between day 5 and 21 of the first cycle of chemotherapy in nanograms per mL.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.\n\nLenalidomide: Given PO\n\nPharmacological Study: Correlative studies","id":"OG000","title":"Arm I (Low-dose Lenalidomide)"},{"description":"Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.\n\nLenalidomide: Given PO\n\nPharmacological Study: Correlative studies","id":"OG001","title":"Arm II (High-dose Lenalidomide)"}],"paramType":"MEDIAN","populationDescription":"Only eligible patients who have lenalidomide concentration measure are considered in the analysis of this secondary outcome measure","reportingStatus":"POSTED","timeFrame":"Between days 5-21 of course 1 and each dose reduction","title":"Pharmacokinetic Parameters of Lenalidomide","type":"SECONDARY","unitOfMeasure":"nanograms per mL"}